ArticleHealth economics review2022

Adjuvant treatment of high-risk melanoma - cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors.

Steffen Wahler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.